NASDAQ: XOMAXoma Royalty Corp Stock
$21.18+0.65 (+3.17%)
Updated Apr 17, 2025
XOMA Price
$21.18
Fair Value Price
N/A
Market Cap
$253.71M
52 Week Low
$18.35
52 Week High
$35.00
P/E
-12.84x
P/B
3.1x
P/S
10.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.49M
Earnings
-$19.29M
Gross Margin
100%
Operating Margin
-39%
Profit Margin
-67.7%
Debt to Equity
1.7
Operating Cash Flow
-$14M
Beta
0.85
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XOMA Overview
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XOMA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XOMA
Ranked#55 of 463
Ranked#55 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important XOMA news, forecast changes, insider trades & much more!
XOMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XOMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XOMA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XOMA is good value based on its book value relative to its share price (3.1x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
XOMA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XOMA due diligence checks available for Premium users.
Valuation
XOMA fair value
Fair Value of XOMA stock based on Discounted Cash Flow (DCF)
Price
$21.18
Fair Value
-$2.23
Undervalued by
1,050.56%
XOMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XOMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.84x
Industry
-177.72x
Market
27.98x
XOMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.1x
Industry
4.05x
XOMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XOMA's financial health
Profit margin
Revenue
$8.7M
Net Income
-$5.3M
Profit Margin
-61.2%
XOMA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XOMA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$221.3M
Liabilities
$139.4M
Debt to equity
1.7
XOMA's short-term assets ($125.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XOMA's short-term assets ($125.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XOMA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XOMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$36.4M
Financing
-$1.1M
XOMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XOMA vs Biotech Stocks
Xoma Royalty Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.